Noxopharm announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful, disfiguring skin condition with no targeted treatment currently available.

The controlled release covers Promarker D, a test that assesses a patient's risk of developing diabetic kidney disease up to four years before symptoms appear, and Promarker Eso, which helps rule out oesophageal cancer in patients suffering from chronic reflux.

The Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced gene and cell therapies at home rather than relying on overseas suppliers.

The grant, announced by Neurizon, will finance an Expanded Access Protocol for NUZ-001, the company's lead drug candidate for amyotrophic lateral sclerosis, commonly known as ALS or motor neurone disease.

Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest-to-treat forms of cancer.

CLINUVEL, a Melbourne- and Singapore-based biopharmaceutical company, has completed development of a proprietary single-use device designed to administer controlled-release drug formulations under the skin.

A hospital in Madrid has reached a notable milestone for OncoSil Medical, with the Australian medical device company confirming that its device has now treated its 100th patient in Spain.

Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new chief executive officer.

Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB.

Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of ALA-101 and opened its first trial site at The Alfred Hospital in Melbourne.

OncoSil Medical has secured $5.6 million in fresh capital from its three biggest institutional shareholders, giving the Sydney-based medical device company the financial firepower to launch its targeted radiation therapy in the United States and Australia after years of regulatory work.

Emyria is on the verge of opening its first clinic in Sydney, marking the company's entry into New South Wales and extending its national network of intensive mental health services into Australia's most populous state.

Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place.

OncoSil Medical has moved to secure a Medicare reimbursement pathway for its targeted internal radiation device in the United States, following the Food and Drug Administration’s humanitarian approval of the treatment for a rare and difficult-to-treat form of bile duct cancer.

Prescient Therapeutics has reached an important enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December.

Tetratherix has exported its first commercial shipment of Tetramatrix polymer to the United States, marking the start of product revenue for the ASX-listed company’s Precision Medicine franchise.

Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study could continue without increasing its planned sample size.